Cargando…

Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial

INTRODUCTION: Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to support effective treatments and alternatives treatment approaches are called for. Photobiomodulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzmaurice, Bethany, Heneghan, Nicola R, Rayen, Asius, Soundy, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244683/
https://www.ncbi.nlm.nih.gov/pubmed/35768101
http://dx.doi.org/10.1136/bmjopen-2021-060058
_version_ 1784738582424977408
author Fitzmaurice, Bethany
Heneghan, Nicola R
Rayen, Asius
Soundy, Andrew
author_facet Fitzmaurice, Bethany
Heneghan, Nicola R
Rayen, Asius
Soundy, Andrew
author_sort Fitzmaurice, Bethany
collection PubMed
description INTRODUCTION: Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to support effective treatments and alternatives treatment approaches are called for. Photobiomodulation therapy has been highlighted as one promising option. A whole-body therapy device (NovoTHOR) has recently been developed with a number of potential advantages for people with chronic pain. Research is needed to consider the feasibility of this device. METHODS AND ANALYSIS: A single-centre single-armed (no placebo group) feasibility study with an embedded qualitative component will be conducted. The intervention will comprise 18 treatments over 6 weeks, with 6-month follow-up, in the whole-body photobiomodulation device. A non-probability sample of 20 adult participants with a clinician diagnosis of chronic axial pain, polyarthralgia, myofascial pain or widespread pain will be recruited (self-referral and clinician referral). Outcome measures will focus on acceptability of trial processes with a view to guiding a definitive randomised controlled trial. Analyses will use descriptive statistics for quantitative aspects. The qualitative element will be assessed by means of a participant-reported experience questionnaire postintervention and semistructured audio-recorded interviews at three stages; preintervention, midintervention and postintervention. The latter will be transcribed verbatim and a reflexive thematic analysis will be used to identify emerging themes. Exploratory outcomes (participant-reported and performance-based measures) will be analysed according to data distribution. ETHICS AND DISSEMINATION: The study has received ethical approval from the Leicester Central Research and Ethics Committee. Findings will be disseminated via local chronic pain groups, public register update, submission for presentation at scientific meetings and open-access peer-reviewed journals, and via academic social networks. TRIAL REGISTRATION NUMBER: NCT05069363.
format Online
Article
Text
id pubmed-9244683
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92446832022-07-14 Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial Fitzmaurice, Bethany Heneghan, Nicola R Rayen, Asius Soundy, Andrew BMJ Open Rheumatology INTRODUCTION: Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to support effective treatments and alternatives treatment approaches are called for. Photobiomodulation therapy has been highlighted as one promising option. A whole-body therapy device (NovoTHOR) has recently been developed with a number of potential advantages for people with chronic pain. Research is needed to consider the feasibility of this device. METHODS AND ANALYSIS: A single-centre single-armed (no placebo group) feasibility study with an embedded qualitative component will be conducted. The intervention will comprise 18 treatments over 6 weeks, with 6-month follow-up, in the whole-body photobiomodulation device. A non-probability sample of 20 adult participants with a clinician diagnosis of chronic axial pain, polyarthralgia, myofascial pain or widespread pain will be recruited (self-referral and clinician referral). Outcome measures will focus on acceptability of trial processes with a view to guiding a definitive randomised controlled trial. Analyses will use descriptive statistics for quantitative aspects. The qualitative element will be assessed by means of a participant-reported experience questionnaire postintervention and semistructured audio-recorded interviews at three stages; preintervention, midintervention and postintervention. The latter will be transcribed verbatim and a reflexive thematic analysis will be used to identify emerging themes. Exploratory outcomes (participant-reported and performance-based measures) will be analysed according to data distribution. ETHICS AND DISSEMINATION: The study has received ethical approval from the Leicester Central Research and Ethics Committee. Findings will be disseminated via local chronic pain groups, public register update, submission for presentation at scientific meetings and open-access peer-reviewed journals, and via academic social networks. TRIAL REGISTRATION NUMBER: NCT05069363. BMJ Publishing Group 2022-06-29 /pmc/articles/PMC9244683/ /pubmed/35768101 http://dx.doi.org/10.1136/bmjopen-2021-060058 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Rheumatology
Fitzmaurice, Bethany
Heneghan, Nicola R
Rayen, Asius
Soundy, Andrew
Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title_full Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title_fullStr Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title_full_unstemmed Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title_short Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
title_sort whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244683/
https://www.ncbi.nlm.nih.gov/pubmed/35768101
http://dx.doi.org/10.1136/bmjopen-2021-060058
work_keys_str_mv AT fitzmauricebethany wholebodyphotobiomodulationtherapyforchronicpainaprotocolforafeasibilitytrial
AT heneghannicolar wholebodyphotobiomodulationtherapyforchronicpainaprotocolforafeasibilitytrial
AT rayenasius wholebodyphotobiomodulationtherapyforchronicpainaprotocolforafeasibilitytrial
AT soundyandrew wholebodyphotobiomodulationtherapyforchronicpainaprotocolforafeasibilitytrial